What is the active ingredient in Tessalon (benzonatate) pearls?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 8, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Tessalon Pearls Active Ingredient

The active ingredient in Tessalon pearls is benzonatate, a non-narcotic oral antitussive agent with the chemical name 2,5,8,11,14,17,20,23,26-nonaoxaoctacosan-28-yl p(butylamino) benzoate, with each capsule containing 200 mg of benzonatate USP. 1

Chemical Structure and Formulation

  • Benzonatate is structurally related to local anesthetics such as tetracaine and procaine, functioning as a polyethoxy ester of 4-(butylamino) benzoic acid 2, 3
  • The molecular weight is 603.7, and the compound exists as a mixture of polyethoxy esters with varying degrees of hydrophobicity 1, 3
  • Each soft gelatin capsule contains inactive ingredients including D&C Yellow No. 10, gelatin, glycerin, and purified water 1

Mechanism of Action

  • Benzonatate works as a peripherally acting antitussive by anesthetizing stretch receptors in the lungs, thereby reducing the cough reflex 4
  • The drug inhibits voltage-gated sodium channels (including Nav1.7) in vagal sensory nerve fibers that mediate cough, similar to local anesthetic effects 3
  • Detectable sodium channel inhibition occurs at concentrations as low as 0.3 μM, which has been documented in human therapeutic use 3

Clinical Dosing

  • The recommended dosage for cough suppression is 100-200 mg three to four times daily according to American College of Chest Physicians guidelines 4
  • Treatment should be limited to short-term symptomatic relief, typically 7-10 days for acute cough 4

Critical Safety Considerations

  • Benzonatate overdose can cause rapid onset of life-threatening toxicity including seizures, cardiac arrest, dysrhythmias, and death within 15 minutes of ingestion 5, 6
  • Fatal outcomes have been documented in children as young as 2 years old from accidental ingestion, with 20 of 31 reported overdose cases resulting in death 5, 7
  • The medication is safe in patients with porphyria, with no evidence suggesting it triggers acute porphyria attacks 4

References

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.